Skip to main content
Log in

Overview

Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Editor
  • Dene Peters
Impact factor
11.5 (2022)
5 year impact factor
10.5 (2022)
Submission to first decision (median)
6 days
Downloads
1,243,370 (2022)

Latest articles

Journal updates

Journal information

Electronic ISSN
1179-1950
Print ISSN
0012-6667
Abstracted and indexed in
  1. BFI List
  2. BIOSIS
  3. Baidu
  4. CAB Abstracts
  5. CLOCKSS
  6. CNKI
  7. CNPIEC
  8. Chemical Abstracts Service (CAS)
  9. Current Contents/Clinical Medicine
  10. Current Contents/Life Sciences
  11. Dimensions
  12. EBSCO
  13. EMBASE
  14. EMBiology
  15. EMCare
  16. Google Scholar
  17. Japanese Science and Technology Agency (JST)
  18. Medline
  19. Naver
  20. OCLC WorldCat Discovery Service
  21. Pathway Studio
  22. Portico
  23. ProQuest
  24. Reaxys
  25. SCImago
  26. SCOPUS
  27. Science Citation Index Expanded (SCIE)
  28. Semantic Scholar
  29. TD Net Discovery Service
  30. UGC-CARE List (India)
  31. Wanfang
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG

Navigation